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Parkinson’s disease (PD) is a progressive neurodegenerative disorder typified by the presence of intraneuronal
inclusions containing aggregated alpha synuclein (αsyn). The progression of parkinsonian pathology and clinical
phenotype has been broadly demonstrated to follow a specific pattern, most notably described by Braak and
colleagues. In more recent times it has been hypothesized that αsyn itself may be a critical factor in mediating
transmission of disease pathology from one brain area to another. Here we investigate the growing body of
evidence demonstrating the ability of αsyn to spread transcellularly and induce pathological aggregation affecting
neurons by permissive templating and provide a critical analysis of some irregularities in the hypothesis that the
progression of PD pathology may be mediated by such a prion-like process. Finally we discuss some key questions
that remain unanswered which are vital to determining the potential contribution of a prion-like process to the
pathogenesis of PD.
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Braak and colleagues devised their widely accepted staging
system of PD progression by assessing the regional distri-
bution of αsyn immunoreactive structures in the brains of
110 αsyn positive subjects (69 incidental and 41 clinically
diagnosed PD patients). According to the Braak model,
the disease process commences in the lower brainstem in
the dorsal motor nucleus of the vagus nerve (DMV), as
well as anterior olfactory structures. The disease then
ascends rostrally from the DMV through susceptible re-
gions of the medulla, pontine tegmentum, midbrain, and
basal forebrain, eventually reaching the cerebral cortex
(Figure 1) [1]. This is a non-random, progressive process,
with specific nuclei and neuronal types giving rise to the
development of Lewy pathology in a stereotypic pattern.
As the pathology advances upwards from the brainstem,
both the severity of the lesions and the clinical manifesta-
tions of the disease increase [2].* Correspondence: lang@uhnres.utoronto.ca
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reproduction in any medium, provided the orThe Braak model of PD staging hinges on the notion
that Lewy pathology is not random: vulnerable sites in the
brain are affected in a predictable topographic sequence
(Figure 1). In support of this, Braak and colleagues have
demonstrated that the cell types in the central nervous
system (CNS) exhibiting a propensity for developing Lewy
pathology share common features. Specifically, projection
neurons with a long, thin, unmyelinated or poorly myelin-
ated axons are particularly susceptible to developing
lesions [3,4]. In agreement with this, cortical and subcor-
tical projection neurons giving rise to long, sturdy, heavily
myelinated axons appear to be resistant to pathology [3].
According to the Braak model, it is this apparent selective
vulnerability of specific neuronal types that accounts for
the predictable regional spread of Lewy pathology ob-
served in PD.
Although the Braak model outlines a pathogenic process
that initiates in the brainstem and advances rostrally, it is
unclear if the brainstem is the site of the initial disease
process. Indeed it is known that PD extends beyond the
boundaries of the CNS, affecting the peripheral nervous
system (PNS), and in particular the enteric nervous system
(ENS). This largely stems from the clinical observation
that PD patients frequently have a wide range of non-
motor symptoms related to dysfunction of the PNS, whichtd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
Figure 1 Staging of Lewy pathology according to the Braak model. Schematic summarizing the progression of Parkinson’s disease as
proposed by Braak and colleagues [1]. According to the Braak model, αsyn deposits in specific brain regions and neuronal types giving rise to
Lewy pathology in a stereotypic, temporal pattern that ascends caudo-rostrally from the lower brainstem (including the dorsal motor nucleus of
the vagus nerve in the medulla then the coeruleus-subcoeruleus complex, raphe nuclei, gigantocellular reticular nucleus in the medulla aand
pons) through susceptible regions of the midbrain (substantia nigra and the pedunculopontine tegmental nucleus) and forebrain (e.g., amygdala)
and into the cerebral cortex (e.g., anteromedial temporal mesocortex, cingulate cortex and later neocortical structures). It is hypothesized that the
disease initiates in the periphery, gaining access to the CNS through retrograde transport along projection neurons from the gastrointestinal tract.
As the disease progresses, the severity of lesions in the susceptible regions increases.
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this, Lewy pathology is found throughout the PNS in both
clinically diagnosed PD patients [5] as well as cases of clin-
ically asymptomatic incidental Lewy body disease (ILBD)
[6-8]. The finding of Lewy Bodies in the brains of asymp-
tomatic individuals without parkinsonism (i.e., ILBD) is of
particular interest as these cases are thought to represent
presymptomatic PD in the very beginning stages of the
disease process [7].
Braak and colleagues have put forth the notion that
the pathogenic process of PD begins when an environ-
mental insult enters the body and subsequently gains ac-
cess to the CNS, where it then spreads trans-synaptically
from one vulnerable brain region to the next [3,9]. This
“dual-hit” hypothesis postulates that the unidentified
neurotropic pathogen enters the brain through both a
nasal and a gastric route. The nasal route is used to ex-
plain the early involvement of olfactory structures, as
well as the olfactory dysfunction that is common in early
PD [3,9]. In support of this, Lewy pathology is found in
both the anterior olfactory nucleus as well as olfactory
bulb mitral cells, the projection neurons that receive in-
put from the olfactory epithelium [1,10].
Despite the initial involvement of the olfactory system,
Braak et al. [3] do not consider olfactory structures to
be the point of departure for Lewy pathology to the restof the brain. Instead, they propose that the unknown
pathogen gains access to the brain through the gastric
system. The gastric route would fit with the early in-
volvement of the ENS in PD. Like olfactory impairment,
gastrointestinal dysfunction is common in PD and
seems to emerge early in the disease course [11], often
preceding clinical parkinsonism by many years [12].
Lewy pathology has long been known to occur in
the gastrointestinal tract of PD patients and is well-
documented in early, mid- and late PD [13-17]. Its pres-
ence in the premotor phase of the disease has been
supported by a recent study of three patients who were
found to have αsyn staining in bowel biopsy samples
obtained 2-5 years before they presented with signs of
PD; such staining was not seen in 23 healthy controls
[16]. In accordance with the Braak model, the cells in
the ENS that are vulnerable to Lewy pathology share the
key characteristics of those vulnerable in the CNS (i.e.
projection neurons with a long, thin, unmyelinated
axon) [18]. If the ENS is the site of induction for a po-
tential PD-causing agent, a pathogenic insult entering
the body via the gastrointestinal tract must then gain ac-
cess to the CNS. The visceromotor projection neurons
of the DMV give rise to preganglionic fibers that innerv-
ate the ENS. Braak et al. [3] have proposed it is these
unmyelinated vagal preganglionic neurons that could
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transported from the ENS into the CNS. This notion is
supported by the observation that these vagal projection
neurons are some of the first cells in the brain to display
Lewy pathology [3]. It may therefore be that a patho-
genic agent enters the body and gains access to the
gastrointestinal tract, invades vulnerable neurons in the
ENS and is subsequently retrogradely transported to
the CNS through vagal preganglionic fibers. Indeed, two
recent reviews have proposed a similar mechanism by
which misfolded proteins in a host of neurodegenerative
diseases may spread from cell-to-cell within the ENS
eventually reaching the CNS [19,20]. Thus, within the
ENS, misfolded proteins, including αsyn, undergo spon-
taneous glycation to form advanced glycation end prod-
ucts (AGEs), which are excreted via exosomes. Once in
the extracellular space, AGEs are recognized by cell
surface receptors for advanced glycation end products
(RAGEs) which act to internalize the misfolded AGE.
AGE-RAGE binding activates multiple intracellular sig-
naling pathways including a positive feedback loop
whereby there is an increased cell surface expression of
RAGE along with induction of oxidative stress and in-
flammation. Through this positive feedback, there is
cell-to-cell spreading of disease throughout the enteric
wall, and perhaps beyond. In the context of Parkinson’s
disease, it is proposed that once in the DMV, the patho-
gen follows an ascending course, spreading from one
susceptible cell group to the next (Figure 1).
Parkinson’s disease as a prion disorder
Transplanted dopamine neurons in humans
The Braak model puts forth evidence for the progressive,
stereotypic spread of an unknown pathogenic insult
from one affected brain region to the next. Building on
this, there has been considerable interest in recent years
in the possibility that this disease progression is medi-
ated in a prion-like fashion, with the spread and seeding
of sequentially involved brain areas by misfolded pro-
teins. The suggestion that PD may be a prion disorder
stems from the observation of Lewy body pathology in
embryonic dopamine neurons transplanted into the pu-
tamen of human PD patients [21-24]. In four separate
case reports, autopsies performed 10-22 years post-
transplantation found evidence of αsyn-positive, Lewy-
body-like inclusions in grafted human dopamine
neurons. Such inclusions are not normally seen in neurons
of such a young age. These inclusions stained positively for
thioflavin-S (indicating the presence of β-sheets) and ubi-
quitin and the affected transplants showed reduced dopa-
mine transporter and tyrosine hydroxylase levels. In
concert with the discussed evidence of a sequential staging
of PD pathology, these observations lead to the proposal
that the progression of PD may be mediated by a prion-like process [25,26]. Furthermore, in contrast to Braak et
al.’s thinking, the proposal was made that αsyn itself may
be the pathogenic factor underlying the spread of the dis-
ease. Adding weight to this proposal, similar prion-like
mechanisms have been proposed for other proteins in-
volved in several other neurodegenerative diseases, includ-
ing Alzheimer’s, Huntington’s and amyotrophic lateral
sclerosis [27-29].
In vitro evidence
Prions are composed of the PrPsc protein, a misfolded
form of endogenous PrPc, and underlie disorders such
as Creutzfeldt-Jakob disease, bovine spongiform enceph-
alopathy and scrapie [30]. The conversion of alpha hel-
ical PrPc to the β-sheet rich PrPsc confers an infectivity
that is the defining feature of a prion [31]. Indeed, as all
other known infectious agents contain either DNA or
RNA, the term prion, derived from the words protein-
aceous and infectious, was given to this unique PrPsc
protein [32]. Though the precise molecular mechanisms
underlying the propagation of the prion protein are un-
known, it is universally accepted that PrPsc acts as a
template upon which native PrPc is refolded into PrPsc.
Extensive in vitro studies have shown that, when incu-
bated at 37°C, monomeric αsyn forms fibrils reminis-
cent of those contained in Lewy bodies in PD [33-35].
Furthermore, existing fibrils can act as seeds, promot-
ing fibrillization of surrounding monomeric αsyn [36].
Closer inspection of the nature of the seed-induced fi-
brils has revealed that addition of seeds produced from
αsyn bearing the A30P mutation to wildtype monomeric
αsyn leads to the generation of fibrils with the same
character as A30P fibrils [37]. Thus it would appear that
the assembly of wildtype fibrils induced by A30P seeds
involves a conformational change in wildtype αsyn to
that of A30P. This process is remarkably similar to that
described for the templated conversion of PrPc to PrPsc.
In the same study it was noted that the addition of
wildtype seeds to monomeric A30P αsyn did not involve
a conversion to the wildtype fibril. This feature of tem-
plated conversion seems to apply to the A30P αsyn mu-
tation responsible for a small number of familial cases of
PD but not to the wildtype form of αsyn responsible for
the majority of cases of PD. Thus, in the context of this
review regarding PD we would define a prion-like mech-
anism of disease propagation as a mechanism by which
native protein with rich α-helical structure is refolded
into a toxic form with high β-sheet structure trigger-
ing the misfolding of further native protein in a self-
perpetuating process. A form of the protein capable of
triggering this process can be conferred from one cell to
another, thus inducing progressive neurodegeneration.
Beyond the test tube, a series of in vitro tissue culture
experiments have demonstrated the following features
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factor implicated in the prion-like spread of PD path-
ology: 1) Fibrillar αsyn has been shown to be transported
via axonal transport [38]. 2) Monomeric and aggregated
forms of αsyn, contained in cytosolic vesicles, are re-
leased from neurons by an unconventional exocytotic
mechanism [39]. 3) Aggregated forms of αsyn (fibrillar
and non-fibrillar oligomers) are taken up into neurons
via conventional endocytosis, whereby they can move
through the endosomal pathway and are eventually
degraded by the lysosome [40]. 4) Transduction of
preformed fibrillar αsyn into cells overexpressing αsyn
results in the formation of insoluble intracellular inclu-
sions recapitulating several key features of Lewy bodies
including size, subcellular localisation, β-pleated sheet
conformation, and hyperphosphorylation and polyu-
biquitination of constituent αsyn [41]. Furthermore,
using C-Myc tagged preformed αsyn fibrils, it has been
demonstrated that soluble endogenous αsyn becomes
recruited to these insoluble intracellular inclusions even-
tually comprising the major component [41]. Several
other studies have employed co-cultures in a wide var-
iety of cell lines to demonstrate the ability of exogenous









Figure 2 Potential mechanisms of neuron-to-neuron transmission of
via (1) leakage from injured cells with compromised membrane integrity. E
and gain access to neighboring neurons (2). Synuclein can also be transmi
Synuclein can be packaged into exosomes which are released and taken u
connection between two cells potentially allowing synuclein to transfer fre
by direct synaptic contact (6).surrounding cells and induce a pathological aggregative
response [42,43]. These cellular mechanisms, by which
αsyn can be both released from and taken up by neurons,
are illustrated in Figure 2. Thus, at the in vitro level there
is compelling evidence that αsyn is capable of spreading
an aggregation-inducing disease-like pathology from one
neuron to another.
In vivo studies
More recent studies have investigated the translation of
these findings in vivo. Desplats et al. grafted green fluor-
escent protein (GFP) labelled mouse cortical neuronal
stem cells (MCNSCs) into the hippocampus of mice
overexpressing human αsyn [43]. Using double immuno-
fluorescence, these authors demonstrated that seven
days post grafting ~2.5% of MCNSCs had taken up αsyn
from the host tissue; 28 days post grafting this number
had risen to ~15%. Although these data demonstrate
host to graft transmission of αsyn in vivo, ultrastructural
analysis of inclusion bodies within grafted cells found no
evidence of the fibril or aggregate formation following
infiltration by αsyn that was evident in their in vitro
studies. A more recent study mimicked more closely the
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[42]. Six months post grafting a small number of grafted
cells were found to contain small human (i.e., host) αsyn
positive punctae. These authors also demostrated that
the structural form of αsyn had no effect on the ability
for cellular uptake in vivo. Thus monomeric, oligomeric
and fibrillar recombinant αsyn were all found in neur-
onal cells following a stereotaxic injection in rats. Inter-
estingly, this phenomenon of αsyn uptake is not limited
to neurons, but has also been demonstrated in astrocytes
both in cell culture and in vivo, whereupon it triggers an
inflammatory response in the recipient cells [44]. As in-
flammation is increasingly implicated in a host of neuro-
degenerative diseases, this process may represent an
alternative means by which αsyn can mediate the pa-
thological progression of PD. A recent study using a
transgenic mouse model of synucleinopathy (TgM83),
demonstrated that inoculation of young asymptomatic
mice with brain homogenates prepared from older
symptomatic mice accelerated the presence of both αsyn
hyperphosphorylated at serine 129 and aggregated αsyn
and significantly decreased survival time [45]. Further-
more, this hastened pathology was absent in αsyn knock-
out animals inoculated with the same brain homogenates
prepared from older symtomatic transgenic mice. This
suggests a strong role for endogenous host αsyn in the
transmission of pathology from affected to unaffected sites
and is consistent with a prion-like mechanism of disease
propagation.
In the aforementioned studies there was no evidence
of a spread of pathologic αsyn to more widespread areas
of the brain distal to the sites of application. However,
two recent studies have expanded upon this. Angot
et al., (2012) used a viral vector (AAV2/6-hu αsyn) to
engineer rat nigral neurons to express human αsyn
which, over time, was transported from nigral cell bodies
to the terminals in the striatum [46]. These authors then
grafted rat ventral mesencephalic neurons into the
striatum and observed transmission of human αsyn
expressed by the virally transduced nigrostriatal cells
into the grafted tissue. Indeed, the extent of transfer of
the virally expressed human αsyn was shown to be of a
much greater magnitude than that observed in previous
studies examining the transfer of αsyn into grafted tis-
sue. Furthermore, human αsyn immunoreactivity within
the grafted cells was shown to be surrounded by a
strong immunoreactivity for rodent αsyn, suggesting that
the human αsyn supplied by the host tissue had induced
a seeding effect in the rodent αsyn present in the grafted
cells. This study demonstrated for the first time that
αsyn can induce a seeding effect in vivo following axonal
transport along the nigrostriatal pathway. However, a
more recent study by Luk et al [47] has demonstrated
that this phenomenon can be even more widespread. Inthis study, brain homogenates from aged transgenic
mice, containing significant levels of aggregated A53T
human αsyn (the first mutation of αsyn discovered in
humans), were injected into the neocortex and striatum
of younger animals long before pathology normally de-
velops. 30 days post injection some level of αsyn path-
ology was evident in the vicinity of the injection sites.
However, 90 days post injection αsyn pathology, reminis-
cent of Lewy bodies and surrounded by astrogliosis and
microgliosis, was widespread throughout the brain.
These inclusions were not apparent in age-matched con-
trol animals innoculated with saline or with homoge-
nates prepared from younger animals. The critical role
of host αsyn to this process was also demonstrated by
the observed lack of pathology following innoculation in
αsyn null mice. In addition, detailed examination dem-
onstrated a recruitment of endogenous murine αsyn to
the pathological inclusions further supporting a permis-
sive templating prion-like process. Mapping studies illus-
trated that it was those brain regions with the most
neuronal connections to the sites of innoculation that
displayed the most severe pathology (frontal cortex and
thalamus) and that there was a relative sparing of re-
gions close by but lacking direct neuronal innervation.
Indeed, based on evidence from their studies the authors
suggest that the distribution of αsyn pathology following
innoculation is suggestive of a trans-synaptic spread.
This contrasts with the recent in vitro findings of
Freundt et al (2012), who found that axon to soma
transfer of αsyn did not require synaptic contacts [38].
Although there is now considerable in vivo evidence of
cell-to-cell transmission of αsyn and recruitment of en-
dogenous αsyn to inclusions reminiscent of Lewy bodies,
a crucial outstanding issue is establishing whether there
is a link between this and the process of neurode-
generation. A recent elegant study has suggested a
causative link between progressive Lewy inclusion for-
mation and neurodegeneration of nigral dopaminergic
cells with correspoding deficit in striatal dopamine and
motor function [48]. The authors demonstrated a clear
time and connectivity dependent spread of Lewy body-
like pathology following intrastriatal injection of fibrillar
αsyn in mice, with expression seen earliest in those brain
regions highly innervated by the striatal injection site
(cortical layers IV and V, and the olfactory bulb) and lat-
ter spread to more distally connected areas (ventral stri-
atum, thalamus, occipital cortex, and commisural and
brainstem fibers). Pathology was particularly abundant
in the dopaminergic cells of the substantia nigra pars
compacta. Intriguingly, at 30 days post injection, ap-
proximately 30% of nigral cells contained αsyn-positive
inclusions, which was accompanied by negligible cell
loss. At 100 days post injection, both the number of cells
bearing αsyn-positive inclusions, the total number of
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concommittantly. These data strongly suggest that ag-
gregation of αsyn may directly precipitate the loss of
nigral dopaminergic neurons that is a fundamental char-
acteristic of PD.
Challenges to reconciling Braak staging with a prion-like
spread of pathology in PD
Clearly there is increasing evidence, both experimental
and clinical, demonstrating that exogenously applied
αsyn can infiltrate surrounding cells and initiate a PD-
like pathological response. However, it remains to be
shown what initiates this process and whether it can ac-
count for disease progression in the human brain. Here
we evaluate the prion hypothesis of PD progression tak-
ing into account the current understanding of the
neuroanatomy and pathology of PD and highlight some
critical remaining questions that need to be addressed
before accepting PD as a prion disorder.
The conserved propagation patterns of αsyn pathology
described by the Braak model could indicate a prion-like
spread of αsyn. According to Braak, vulnerable brain re-
gions are affected in a predictable sequence, progressing
in a stereotypical caudal-rostral pattern starting in the
lower brainstem. One could hypothesize that pathogenic
αsyn is transported to anatomically connected brain re-
gions along the prescribed route of progression, seeding
αsyn aggregation in each vulnerable region encountered.
Whether the pattern and progression of pathology can
be generalized to the predictable, sequential involvement
of vulnerable sites as Braak describes, however, remains
controversial. The Braak model postulates that Lewy
pathology in the lower brainstem is necessary for the
later appearance of Lewy pathology in more rostral
structures [1]. However, this may be an artifact of their
pre-selection of cases on the basis of involvement of
DMV. Multiple studies have challenged the Braak sta-
ging scheme, reporting cases with inclusions throughout
the brain but with preservation of medullary nuclei
[8,49-51]. In fact, recent reports suggest that the Braak
system fails to classify upwards of 50% of αsyn immuno-
reactive cases [50,52,53]. The pathological regional het-
erogeneity between PD cases suggests Braak’s proposed
pathway is not the only possible route of spread and
pathology may even emerge simultaneously in multiple
subcortical and cortical regions. Such cell autonomous
protein misfolding would argue against a Braak model of
PD staging. One might expect that a cell autonomous
process would better explain genetic causes of PD asso-
ciated with Lewy bodies. However, that the site of initial
emergence of disease may well be variable and perhaps
multiple (possibly within certain anatomical constraints)
leading to a heterogeneous phenotype, does not preclude
that a prion-like mechanism still might govern spread ofdisease through the brain from these multiple and varied
departure points.
Challenges also exist for the proposed “gut to brain”
spread of Lewy pathology. Rather than suggesting initial
involvement of the ENS with subsequent spread to the
DMV, Beach et al (2010) have advocated a "brain to gut"
direction of transmission given their findings of a rostro-
caudal gradient of phosphorylated αsyn in the GI tract
and the known richest vagal innervation of the upper
gut [5]. The recent report of Del Tredici and Braak
(2012) showing evidence for involvement of the spinal
cord only after involvement of the brain also raises ques-
tion about the earliest involvement of at least some ENS
regions [54].
Another prerequisite of the Braak model is that the
severity of the lesions in the affected brain regions will
increase as the disease progresses [1]. It would therefore
be expected that the DMV, Braak’s point of departure
for Lewy pathology in the brain, would have more se-
vere pathology than the rostral regions said to be af-
fected later in the disease. This, however, is not true in
all cases. In one study, upwards of 65% of cases had
αsyn loads in the substantia nigra and locus coeruleus
that were roughly equivalent to that found in the DMV
[55]. Further still, there are reports of severe involve-
ment of the substantia nigra without any prominent
DMV pathology [56,57]. This lack of significant αsyn
pathology in the DMV compared to more rostral struc-
tures cannot be explained by neuronal loss, as these
cases had well preserved neurons. For the Braak-prion
hypothesis to account for these cases, pathogenic αsyn
would have to spread and seed very rapidly to all vulner-
able brain regions once the disease process is initiated,
which does not fit with the protracted disease course of
idiopathic PD. Alternatively, mechanisms underlying
seeding and subsequent aggregation and cell death may
be dissociated.
One possible explanation for the inconsistencies be-
tween the Braak model and the conflicting reports may
be that spreading of pathology can occur in both an an-
terograde and retrograde direction. Braak and colleagues
initially hypothesized that while the olfactory system is
affected very early in the disease process, olfactory struc-
tures are not the point of departure for Lewy pathology
to the rest of the brain, despite connections with cortical
and subcortical regions [1]. Subsequent observations
from a growing number of groups, including Braak and
colleagues, however, have suggested that Lewy pathology
may indeed progress along olfactory pathways [9,58-60].
Lerner and Bagic [26] subsequently expanded upon this
by proposing a complementary hypothesis to the Braak
model, in which they emphasize the possibility of an-
terograde spread of the pathogen through the olfactory
tubercle and bulb to the brainstem, in addition to the
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vagus, as described by Braak et al. [1]. The addition of
this olfactory route of progression may reconcile some
discrepancies with the original Braak model. Although,
the bi-directional spread of a pathogen may be at odds
with the Braak staging scheme, it is not inconsistent
with the concept of neuronal spread of a pathogen in a
prion-like fashion. Indeed, Lerner and Bagic suggested
such a prion-like mechanism may underlie the neurode-
generative process in PD [26].
A further explanation for the reported inconsistencies
with the Braak model may be the clinical diversity of
PD. Different subtypes of PD may have different under-
lying pathological patterns. In support of this, Halliday
et al. [61] found that PD patients with a younger age of
onset and a long clinical course had pathology that fit
with the Braak model, whereas patients with older onset
and shorter disease duration did not. This suggests that
clinical phenotype may predict the pattern of pathology
that underlies PD. The fact that Braak and colleagues
only selected cases in which the DMV was positive for
αsyn immunoreactivity may account for some of these
apparent discrepancies, as they may have only examined
a select subtype of PD. More recent large-scale neuro-
pathological studies tend to include all cases that are
positive for αsyn immunoreactivity, regardless of which
brain regions were affected, and as a result may include
a more diverse profile of PD and its subtypes. It may
therefore be that a prion-like spread of αsyn in a pattern
predicted by the Braak model does indeed occur in PD
but only in certain subtypes of the disease.
A key outstanding issue when considering using Lewy
body pathology to define the progression of PD is regard-
ing whether the Lewy body itself is harmful or protective.
Traditionally, the presence of Lewy bodies in sites prone
to neurodegeneration has supported the dogma that the
Lewy body is detrimental to neuronal survival. However,
in recent years many studies have suggested that Lewy
body formation is a protective cellular mechanism to se-
quester toxic αsyn aggregates and even aid their degrad-
ation by an aggresome-like mechanism [62-65]. In some
cases cells containing Lewy bodies have been described as
having a healthier morphology than neighboring Lewy
body negative cells [66]. Furthermore, in vitro studies have
demonstrated that cell death can precede Lewy body for-
mation [67] and in PD it has been shown that the majority
of cells undergoing apoptosis do not contain Lewy bodies
[68]. As the Lewy body may in fact represent a cell that is
resisting neurodegeneration, caution must be used in
employing it to define disease progression. Indeed, a recent
study examining the relationship between nigral cell loss,
distribution of Lewy bodies and disease duration in PD
found no evidence to support a correlation between Lewy
body distribution or density and neurodegeneration [69].It is vital to keep this issue in mind when also consid-
ering the selective susceptibility of certain cell types and
specific brain regions to Lewy pathology. While the
Braak model describes projection neurons with a long,
thin, unmyelinated axons as the cell type that is prone
to Lewy pathology [3,4], it is not known why these neu-
rons are susceptible. Although many explanations could
be provided to account for differences between the hu-
man disease and animal models, it is interesting to note
that the recent important study by Luk et al. [47], which
provides some of the strongest evidence to date for
transcellular propagation of αsyn pathology, demon-
strated most marked involvement of heavily myelinated
projections, including the internal capsule. Furthermore,
it is not clear why some regions with Braak’s “vulner-
able” cell types are affected whereas many other anatom-
ically connected/neighboring regions with similar cell
types are not. Such cryptic susceptibility is further
highlighted in Braak’s detailed description of a non-
geographical pattern of Lewy pathology in specific sub-
cortical structures in earlier disease versus a more
diffuse spreading throughout the cortex in later stages
[1]. It therefore seems that αsyn propagates differently
according to the type of brain tissue it encounters; how-
ever, it is not clear how or why this would be the case.
To further complicate matters, according to the Braak
model, the neuronal type prone to developing Lewy
pathology in PD is specific to PD and distinguishes PD
from other synucleinopathies [3]. Therefore, the prion-
like spread of αsyn must discriminate between cell types
across different synucleinopathies. Furthermore, while
abnormal aggregation of αsyn is the dominant patho-
logical hallmark of synucleinopathies, the nature of αsyn
aggregation is distinct between different disorders. For
example, PD, Parkinson’s disease dementia (PDD) and
dementia with Lewy bodies (DLB) are characterized by
αsyn deposits in neuronal Lewy bodies and Lewy
neurites, whereas multiple system atrophy (MSA) is de-
fined by abnormal filamentous deposition of αsyn in the
nuclei and cytoplasm of both oligodendrocytes and
neurons [70-72]. If prion-like αsyn seeding plays an im-
portant role in the pathogenesis of neurodegenerative
disease then how and why αsyn behaves differently in
different diseases must be addressed (see below). In this
context, using the Lewy body as a structural marker for
the progression of the disease may not be appropriate.
For example Kramer et al., have demonstrated that, in
contrast to the relatively small number of cortical Lewy
bodies, there are a number of small presynaptic αsyn ag-
gregates in DLB, which may account for the significant
cognitive impairment in this disease [63]. Similarly,
Milber et al found evidence of neuronal dysfunction pre-
ceding Lewy pathology in the nigra in PD [73]. These
data suggest that synaptic dysfunction can occur without
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using the Lewy body alone as a marker of pathological
progression is not sufficient to predict the spread of
disease.
Finally, if the progression of PD can be explained by a
Braak-prion-like spread, a critical question that must be
addressed is what initiates the process in the first place?
Braak’s dual-hit hypothesis postulates that an environ-
mental neurotropic insult is responsible [3,9]. While the
Braak model proposes a viral pathogen, a recent study in
mice demonstrated that a peripherally administered en-
vironmental toxin (i.e. rotenone) may induce a Braak-
like spread of αsyn pathology in the CNS [74]. Although
this has not been shown in the human condition, such
results do support the hypothesis of an environmental
insult triggering the Braak’s cascade of pathology seen in
PD. What is not clear, however, is how an environmental
insult could induce the involvement of systems outside
of Braak’s continuous chain of projection neurons that
are presumably isolated from the environment. Perhaps
one of the most challenging facts to reconcile with this
theory is the very early involvement of the cardiac sym-
pathetic nerves seen in PD and in the presumed pre-
clinical state of incidental Lewy body disease [75].
Other challenges to the prion hypothesis
In addition to the issues outlined above, there are critical
questions in the defining of PD as a prion disorder that
must be addressed. One substantial issue is indeed se-
mantic. As the word prion itself derives from the words
“protein” and “infectious”, to define PD as a prion dis-
order mediated by αsyn, we must demonstrate that αsyn
is capable of “infectivity”. It has been suggested that, due
to an apparent lack of microbiological transmissibility
and propagation within communities, all amyloidogenic
proteins capable of permissive templating be termed
“prionoids” [27]. It remains possible that difficulties in
verifying an infectious nature of αsyn may be due to the
length of time required for the process to occur in vivo.
Indeed in human post mortem studies, Lewy-like path-
ology was not observed in grafted tissue 18 months post
graft [76]. Accumulation was apparent four years post
graft, but not until 10-14 years post graft was full Lewy
pathology evident [21]. There are likely several features
of both the host and the "infectious" agent that influence
the cell to cell transfer, effectiveness of permissive tem-
plating, and the distribution and nature of the resulting
pathology. For example, in classical prion diseases, the
biochemical nature of the prion protein PrPsc and the
genetic makeup of the host (M/V at codon 129) have
major influences on the nature and distribution of the
underlying pathology (and as a consequence the clinical
manifestations). The same types of processes may influ-
ence the distribution of Lewy body pathology in PD andeven determine whether the final disease presentation is
PD or that of another synucleinopathy. Furthermore, if
indeed αsyn is responsible for a prion-like propagation
of the disease, understanding the relatively delayed
propagation of αsyn pathology post symptom onset, as
compared to the rapid process of conventional prion dis-
orders once symptomatic, could inform the development
of therapies to slow the progression of both PD and
prion diseases.
We have reviewed considerable experimental evidence
supporting the premise that αsyn can be released from
and enter neighbouring neurons, and induce aggregation
of native αsyn in vitro. However, there are some caveats to
these experimental settings that necessitate caution in ex-
trapolating these data to the human brain in PD. Firstly,
not all tissue culture studies find that supplying exogenous
αsyn in the surrounding media is sufficient for infiltration
into cells. Indeed in order to get meaningful internalisa-
tion Luk and colleagues had to make use of cationic lipo-
somes to facilitate entry of αsyn into the cell [41]. A
further caution is required in interpreting the significance
of data demonstrating the transmission of αsyn in animal
studies employing mice genetically engineered to over-
express αsyn, thus presumably enhancing any host-
to-graft transmission, although more recent work
demonstrates similar changes in non-transgenic animals
[48]. Furthermore, the applicability of animal studies
employing direct stereotaxic application of αsyn to the
brain to the initiation and propagation of idiopathic PD
remains to be shown. Although the recent results of Luk
and colleagues in non-transgenic animals [48] are impres-
sive and very promising, it must be admitted that the rele-
vance of using very high concentrations of preformed
artificial αsyn fibrils to human PD is unknown. Thus, fur-
ther studies are required to demonstrate unequivocally
that enough αsyn can be released and infiltrate surround-
ing tissues, by physiological means, to induce aggregation
in vivo. Secondly, there is controversy in the literature re-
garding the structural assembly of αsyn required to induce
inclusion formation. In the many studies employing
co-culture and those stereotaxically implanting cells
overexpressing αsyn, the structural nature of the infiltrat-
ing αsyn is unclear [42,77]. Tissue culture studies have
shown that monomeric, oligomeric and fibrillar αsyn can
be taken up by cells [42]. Thus, in co-culture experiments,
and those stereotaxically implanting cells overexpressing
αsyn, it could be any of these structural forms leading to
the aggregate formation within the host. It should also be
emphasized that much of this discussion hinges on the
concept that the insoluble fibrillar protein aggregates are
responsible for cell death, whereas there is increasing evi-
dence implicating soluble oligomers as potential culprits
in the pathogenesis of neurodegenerative diseases such as
PD [78]. Thirdly, the degradation of different assemblies
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cell culture studies suggest that exogenously applied
monomeric αsyn is quickly degraded by the lysosome
whereas fibrillar αsyn endures [41]. Conversely, other cell
culture studies have found that oligomeric αsyn is de-
graded by the lysosome, and that monomeric αsyn rapidly
and directly translocates to cellular membranes thus
resisting lysosomal degradation and is therefore the more
likely disease spreading form [40]. Finally, although the re-
cent studies by Angot et al and Luk et al. [46,47] have
demonstrated a putative trans-synaptic spread of αsyn
pathology in vivo, crucially, the transfer of αsyn through
the neuroanatomical pathways implied in Braak’s staging
scheme has not yet been shown. Indeed in the study of
Luk et al. [47], stereotaxically applied αsyn was demon-
strated to travel in both an anterograde and retrograde
manner, being evident in both the thalamus and the
substantia nigra pars compacta following a striatal applica-
tion in mice. As mentioned above, such a bidirectional
spread seems at odds with Braak staging in PD, although
does not argue against a prion-like disease mechanism.
Future in vitro studies should be performed to investigate
the ability of αsyn applied in the ENS or olfactory bullb to
spread along the pathways described by Braak staging.
The occurrence of Lewy bodies in transplanted fetal
nigral neurons in patients with PD has been a strong
incentive to consider a prion-like spread of pathology.
However, not all case reports find pathology in grafted
tissue [79]. In those that do, Lewy bodies are present
“within a minority” of grafted cells [22] although it
should be noted that the proportion of transplanted
neurons reported to contain Lewy bodies is almost
identical to the proportion of Lewy body positive neu-
rons in the substantia nigra in Parkinson’s disease. Des-
pite this, it must be acknowledged that Lewy bodies
contain much more than aggregated αsyn and occur in
many disorders in which αsyn is not believed to be a
primary contributor to the overall pathogenesis. A
more plausible explanation may be that multiple other
toxic factors that are known to exist in the PD brain,
such as proinflammatory cytokines, reactive oxygen
species (supported by the extent of neuromelanization
uncharacteristic of such young neurons [21]) and pro-
apoptotic factors, may damage the cell leading to a dis-
ruption of cellular processes and explain the presence
of Lewy bodies in previously healthy grafted dopamin-
ergic cells. This is not to say that αsyn cannot be impli-
cated in such alternate cell death mechanisms. For
example, as previously discussed, αsyn can be taken up
into microglia and induce the production and excretion
of inflammatory mediators.
A final challenge to the prion-like propagation of αsyn
pathology accounting for PD is the observation that
Lewy pathology is not necessary for nigral degenerationand the clinical presence of parkinsonism. While patho-
logical studies on genetic forms of PD are limited, it is
clear that at least some of these patients do not show
classic Lewy pathology. Indeed, in the case of LRRK2
mutations even within a single family, a spectrum of
pathology has been observed among family members
with manifesting PD, ranging from those completely
lacking any synuclein pathology, to those with signifi-
cant αsyn aggregation [80-84]. Furthermore a recent
study comparing neuronal dysfunction in relation to
Braak stage in patients with PD, individuals with ILBD
and controls has demonstrated that both cellular dys-
function (loss of tyrosine hydroxylase) and neuro-
degeneration can precede Lewy body pathology in ILBD
[73]. These findings are in direct contrast to those of
Luk and colleagues [47] who suggest quite the reverse,
that synuclein pathology precedes cell loss. Clearly, fur-
ther studies will need to be performed to address these
concerns.
Conclusions
Recent years have seen a tremendous surge of interest in
the possibility that neurodegenerative diseases, including
PD, could develop and progress via non-cell autono-
mous means, spreading by transcellular mechanisms
with seeding and subsequent permissive templating, in a
prion-like fashion. If these mechanisms are indeed inte-
gral to the pathogenesis of PD and other diseases, this
could have important therapeutic implications, as re-
cently discussed in more detail elsewhere [85,86]. These
possibilities include treatments designed to block the re-
lease or uptake of the pathogenic protein, increase its
extracellular clearance by microglia, inhibit protein as-
sembly by, for example, nanomaterials [87] and increase
degradation of aggregates, for example, by lysosomes.
Currently available drugs may have additional inhibitory
effects on the endocytosis mechanism that mediates the
internalization of αsyn oligomers [88]. Another approach
that could be available for clinical study in the near fu-
ture might be the use of monoclonal antibodies or
immunization therapy, which might be expected to have
greater potential for benefit if there is indeed an extra-
cellular phase of αsyn transmission. In light of the fact
that there is currently no available therapy to slow or
halt the pathological progression of PD, the potential
therapeutic implications of a therapy targeted at the
mechanism responsible for the transmission of path-
ology from one region to another are formidable. Thus,
it is vital that further in vitro and in vivo studies are
performed to validate the potential involvement of αsyn
as a prion-like factor and tease out the mechanisms by
which αsyn may be responsible for disease progression
in the human condition. However, in view of the unre-
solved challenges highlighted in this review, caution
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prion-like process, particularly in all cases of PD. Indeed,
the mechanisms contributing to the progression of the
disease may be as variable as the disease itself.
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